Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1309 | ELISA and Rapid test to detect antibodies against COVID-19 Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003095 | Collagen Diseases NIH | 0.35 |
| D012216 | Rheumatic Diseases NIH | 0.32 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
SAR-COVID is a national, multicenter, prospective, observational longitudinal registry of consecutive patients with diagnosis of rheumatic diseases treated or not with immunomodulatory and/or immunosuppressive drugs and SARS-CoV-2 infection (asymptomatic or COVID-19). Hypothesis: Patients with rheumatic diseases who are under chronic treatment with immunomodulatory and/or immunosuppressive drugs more frequently have an asymptomatic infection, a milder COVID-19 and lower mortality than patients with rheumatic diseases without immunomodulatory and/or immunosuppressive treatments.
Description: Death caused by SARS-CoV-2 infection
Measure: Mortality Time: 2 monthDescription: Hospitalization because of SARS-CoV-2 infection
Measure: Hospitalization Time: 2 monthDescription: To describe clinical presentation of SARS-CoV-2 infection in patients with rheumatic diseases
Measure: SARS-CoV-2 infection presentation Time: 1 monthDescription: Proportion of patients admitted at the intensive care unit
Measure: Admission at the intensive care unit Time: 2 monthDescription: Proportion of patients who required invasive mechanical ventilation
Measure: Invasive mechanical ventilation Time: 2 monthDescription: Proportion of patients who had complications associated with COVID-19 infection and describe them
Measure: COVID-19 Complications Time: 2 monthDescription: Proportion of patients fully or partially recovered after COVID-19 infection.
Measure: Recovery rate Time: 2 monthAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports